Article Details
Retrieved on: 2018-04-16 23:33:45
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
<div>This week, it sold some brands to <b>Charterhouse Capital Partners</b>' Cooper-Vemedia drugs manufacturing arm for 158 million euros.” “Zentiva is a robust business with a highly talented workforce and we believe it has demonstrated its potential for growth,” said Olivier Brandicourt, Sanofi's chief executive ...</div>
Article found on:
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here